Court Ruled Liquidia Infringed on Patent
A district court judge found Liquidia infringed on two claims within a United Therapeutics patent.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you trust that patent litigation between drug companies generally puts patient needs first?
The U.S. District Court of Delaware ruled that Liquidia infringed on two claims of a United Therapeutics patent, known as the '327 patent. While the court upheld the validity of those specific claims, it invalidated four other asserted claims in the same patent.
Why it matters
The ruling creates legal uncertainty for Liquidia regarding the market availability of its drug YUTREPIA. United Therapeutics has sought injunctive relief to restrict the product, forcing Liquidia to plan for potential label changes or distribution limitations.
The court confirmed that claims 1 and 14 of the '327 patent are valid and infringed by Liquidia. The remaining four of the six total asserted claims were determined to be invalid.
The players
Liquidia
This is a Morrisville, N.C.-based pharmaceutical company currently navigating legal challenges regarding its drug product.
United Therapeutics
This is a biotechnology company that holds the '327 patent and has requested injunctive relief against its competitor.
The details
Liquidia, headquartered in Morrisville, N.C., intends to appeal the court decision following the recent ruling. The company also plans to submit a supplement to its New Drug Application to remove the PH-ILD indication from the YUTREPIA label in response to the legal outcome.
Timeline
The FDA approved YUTREPIA in 2025.
A District Court issued the ruling on patent claims on September 30, 2026.
Parties must submit a form of judgment to the court by October 7, 2026.
The Tech Race
The ruling follows the procedural pattern set by the Hatch-Waxman Act's patent litigation framework for pharmaceutical market entries. This decision highlights the ongoing legal volatility that characterizes competition within the specialized biotech sector.
Patients who rely on YUTREPIA for treatment may face future disruptions in access depending on the final court-ordered remedies. Potential label changes or distribution limits could alter how the medication is prescribed or obtained by healthcare providers.
The takeaway
This case illustrates the significant financial and operational risks companies face when entering markets protected by established pharmaceutical patents. Stakeholders should monitor upcoming court filings to determine the precise impact on product availability and labeling requirements.
Further reading
For more context on the regulatory and patent environment, visit the United States Biotech section.
Live Poll
Do you trust that patent litigation between drug companies generally puts patient needs first?
